儿童疫苗不会诱导产生针对严重急性呼吸综合征冠状病毒（SARS-CoV）的交叉反应。
Children's vaccines do not induce cross reactivity against SARS-CoV.
作者信息
Yu Yang, Jin Huali, Chen Ze, Yu Qingling L, Ma Yijie J, Sun Xiaolin L, Wang Bin
机构信息
State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing, China.
出版信息
J Clin Pathol. 2007 Feb;60(2):208-11. doi: 10.1136/jcp.2006.038893.
Abstract
In contrast with adults, children infected by severe acute respiratory syndrome-corona virus (SARS-CoV) develop milder clinical symptoms. Because of this, it is speculated that children vaccinated with various childhood vaccines might develop cross immunity against SARS-CoV. Antisera and T cells from mice immunised with various vaccines were used to determine whether they developed cross reactivity against SARS-CoV. The results showed no marked cross reactivity against SARS-CoV, which implies that the reduced symptoms among children infected by SARS-CoV may be caused by other factors.
摘要
与成人相比，感染严重急性呼吸综合征冠状病毒（SARS-CoV）的儿童临床症状较轻。因此，据推测接种多种儿童疫苗的儿童可能会产生针对SARS-CoV的交叉免疫。使用来自用各种疫苗免疫的小鼠的抗血清和T细胞来确定它们是否产生针对SARS-CoV的交叉反应性。结果显示对SARS-CoV没有明显的交叉反应性，这意味着感染SARS-CoV的儿童症状减轻可能是由其他因素引起的。
相似文献
1
Children's vaccines do not induce cross reactivity against SARS-CoV.儿童疫苗不会诱导产生针对严重急性呼吸综合征冠状病毒（SARS-CoV）的交叉反应。
J Clin Pathol. 2007 Feb;60(2):208-11. doi: 10.1136/jcp.2006.038893.
2
Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice.3种针对严重急性呼吸综合征（SARS）或类SARS冠状病毒的DNA疫苗在小鼠体内诱导的体液免疫和细胞免疫反应
Clin Vaccine Immunol. 2009 Jan;16(1):73-7. doi: 10.1128/CVI.00261-08. Epub 2008 Nov 5.
3
Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein.严重急性呼吸综合征冠状病毒（SARS-CoV）与第1组动物冠状病毒之间的双向抗原交叉反应是通过SARS-CoV核蛋白N端区域的一个抗原位点介导的。
J Virol. 2007 Dec;81(24):13365-77. doi: 10.1128/JVI.01169-07. Epub 2007 Oct 3.
4
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.用编码严重急性呼吸综合征冠状病毒（SARS-CoV）S蛋白受体结合域（RBD）的重组腺相关病毒（rAAV）进行预刺激，并使用针对T细胞表位的RBD特异性肽进行加强刺激，可提高针对SARS-CoV感染的体液免疫和细胞免疫反应。
Vaccine. 2008 Mar 20;26(13):1644-51. doi: 10.1016/j.vaccine.2008.01.025. Epub 2008 Feb 4.
5
[A preliminary investigation on the serological and epidemiological characteristics of severe acute respiratory syndrome in children].[儿童重症急性呼吸综合征的血清学及流行病学特征初步调查]
Zhonghua Er Ke Za Zhi. 2004 Nov;42(11):840-4.
6
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.恢复期 SARS 患者血清抗体和免疫动物对 SARS-CoV-2 的交叉中和作用。
Sci Adv. 2020 Nov 6;6(45). doi: 10.1126/sciadv.abc9999. Print 2020 Nov.
7
Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.针对 SARS-CoV-1 刺突蛋白 S2 亚基的单克隆抗体与新出现的 SARS-CoV-2 发生交叉反应。
Euro Surveill. 2020 Jul;25(28). doi: 10.2807/1560-7917.ES.2020.25.28.2000291.
8
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.鉴定严重急性呼吸综合征冠状病毒刺突糖蛋白S2结构域上一个能够诱导中和抗体的抗原决定簇。
J Virol. 2004 Jul;78(13):6938-45. doi: 10.1128/JVI.78.13.6938-6945.2004.
9
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV.严重急性呼吸综合征冠状病毒的T细胞免疫：对中东呼吸综合征冠状病毒疫苗研发的启示。
Antiviral Res. 2017 Jan;137:82-92. doi: 10.1016/j.antiviral.2016.11.006. Epub 2016 Nov 11.
10
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections.新冠病毒和非典病毒感染之间的交叉反应性抗体反应。
Cell Rep. 2020 Jun 2;31(9):107725. doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
引用本文的文献
1
SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection.严重急性呼吸综合征冠状病毒 2 型：了解 ACE2 和 TMPRSS2 的转录调控，以及 p53 密码子 72 处单核苷酸多态性（SNP）在固有免疫反应对病毒感染中的作用。
Int J Mol Sci. 2021 Aug 12;22(16):8660. doi: 10.3390/ijms22168660.
2
Coronavirus Disease 2019 in Children.2019年儿童冠状病毒病
Front Pediatr. 2021 May 28;9:668484. doi: 10.3389/fped.2021.668484. eCollection 2021.
3
Managing children with brain tumors during the COVID-19 era: Don't stop the care!在新冠疫情时代管理患有脑肿瘤的儿童：不要停止护理！
Comput Struct Biotechnol J. 2021 Jan 12;19:705-709. doi: 10.1016/j.csbj.2021.01.005. eCollection 2021.
4
The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.卡介苗与新冠病毒的离奇案例：尚无定论
Vaccines (Basel). 2020 Oct 16;8(4):612. doi: 10.3390/vaccines8040612.
5
COVID-19 in children: Could pertussis vaccine play the protective role?儿童 COVID-19：百日咳疫苗能发挥保护作用吗？
Med Hypotheses. 2020 Dec;145:110305. doi: 10.1016/j.mehy.2020.110305. Epub 2020 Sep 28.
6
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.冠状病毒抗体介导免疫的系统评价：动力学、保护相关性及与严重程度的关系。
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
7
Can data from paediatric cohorts solve the COVID-19 puzzle?儿科队列数据能否解开 COVID-19 之谜？
PLoS Pathog. 2020 Sep 9;16(9):e1008798. doi: 10.1371/journal.ppat.1008798. eCollection 2020 Sep.
8
Improving Non-specific Immunity to Coronavirus Disease (COVID-19) by the Novelty, Diversity, and Quantity of Antigen.通过抗原的新颖性、多样性和数量提高对冠状病毒病（COVID-19）的非特异性免疫力。
Front Public Health. 2020 Jul 28;8:393. doi: 10.3389/fpubh.2020.00393. eCollection 2020.
9
A Review on Currently Available Potential Therapeutic Options for COVID-19.关于新冠病毒病当前可用潜在治疗方案的综述
Int J Gen Med. 2020 Jul 24;13:443-467. doi: 10.2147/IJGM.S263666. eCollection 2020.
10
A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.冠状病毒抗体介导免疫的系统评价：抗体动力学、保护相关性以及抗体反应与疾病严重程度的关联
medRxiv. 2020 Apr 17:2020.04.14.20065771. doi: 10.1101/2020.04.14.20065771.
本文引用的文献
1
Long-term sequelae of SARS in children.儿童严重急性呼吸综合征的长期后遗症。
Paediatr Respir Rev. 2004 Dec;5(4):296-9. doi: 10.1016/j.prrv.2004.07.012.
2
Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice.由全病毒制备的灭活严重急性呼吸综合征冠状病毒疫苗可在BALB/c小鼠中诱导产生高水平的中和抗体。
DNA Cell Biol. 2004 Jun;23(6):391-4. doi: 10.1089/104454904323145272.
3
Severe acute respiratory syndrome among children.儿童严重急性呼吸综合征
Pediatrics. 2004 Jun;113(6):e535-43. doi: 10.1542/peds.113.6.e535.
4
[Determination and comparison of anti-SARS antibody in children and adults].[儿童与成人抗SARS抗体的测定及比较]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Apr;12(2):217-9.
5
A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21.通过在携带人脊髓灰质炎病毒受体的转基因小鼠TgPVR21中进行黏膜感染建立的脊髓灰质炎模型。
Virology. 2004 Mar 30;321(1):87-100. doi: 10.1016/j.virol.2003.12.008.
6
Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein.严重急性呼吸综合征冠状病毒刺突蛋白的HLA-A*0201限制性CD8+T细胞表位SSp-1的鉴定
Blood. 2004 Jul 1;104(1):200-6. doi: 10.1182/blood-2003-11-4072. Epub 2004 Mar 11.
7
[Clinical analysis of pediatric SARS cases in Beijing].[北京儿童非典病例的临床分析]
Zhonghua Er Ke Za Zhi. 2003 Aug;41(8):574-7.
8
Inflammatory cytokine profile in children with severe acute respiratory syndrome.重症急性呼吸综合征患儿的炎性细胞因子谱
Pediatrics. 2004 Jan;113(1 Pt 1):e7-14. doi: 10.1542/peds.113.1.e7.
9
Children hospitalized with severe acute respiratory syndrome-related illness in Toronto.在多伦多因严重急性呼吸综合征相关疾病住院的儿童。
Pediatrics. 2003 Oct;112(4):e261. doi: 10.1542/peds.112.4.e261.
10
SARS: understanding the coronavirus: apoptosis may explain lymphopenia of SARS.严重急性呼吸综合征：了解冠状病毒：细胞凋亡可能解释严重急性呼吸综合征的淋巴细胞减少症。
BMJ. 2003 Sep 13;327(7415):620. doi: 10.1136/bmj.327.7415.620-b.
Zotero 插件